Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma
NCT00392834 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34
Last updated 2018-06-06
Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with newly diagnosed, HIV-associated Burkitt's lymphoma.
Conditions
Interventions
- BIOLOGICAL
-
given subcutaneously
- BIOLOGICAL
-
given subcutaneously
- BIOLOGICAL
-
given IV
- DRUG
-
given IV
- DRUG
-
given intrathecally
- DRUG
-
doxorubicin hydrochloride
given IV
- DRUG
-
etoposide
given IV
- DRUG
-
ifosfamide
given IV
- DRUG
-
leucovorin calcium
given IV
- DRUG
-
liposomal cytarabine
given intrathecally
- DRUG
-
methotrexate
given intrathecally
- DRUG
-
therapeutic hydrocortisone
given intrathecally
- DRUG
-
vincristine sulfate
given IV
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
The Emmes Company, LLC
collaborator INDUSTRY -
AIDS Malignancy Consortium
lead NETWORK
Principal Investigators
-
Ariela Noy, MD · Memorial Sloan Kettering Cancer Center
-
David M. Aboulafia, MD · Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center
-
Lawrence D. Kaplan, MD · University of California, San Francisco
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 120 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-09-30
- Primary Completion
- 2011-07-31
- Completion
- 2013-07-31
Countries
- United States
Study Locations
More Related Trials
-
Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma
NCT00039195 ·Status: COMPLETED ·Phase: PHASE2
-
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
NCT06209619 ·Status: RECRUITING ·Phase: PHASE1
-
Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma
NCT00689845 ·Status: UNKNOWN ·Phase: NA
-
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
NCT00335140 ·Status: TERMINATED ·Phase: PHASE2
-
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
NCT06834373 ·Status: RECRUITING ·Phase: PHASE2
-
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
NCT00126191 ·Status: TERMINATED ·Phase: PHASE2
-
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
NCT00369681 ·Status: COMPLETED ·Phase: PHASE2
-
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
NCT05389423 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
NCT06425302 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04285268 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger
NCT00290498 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
NCT01092182 ·Status: COMPLETED ·Phase: PHASE2
-
Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib
NCT02636322 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
NCT00670358 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
NCT01856192 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma
NCT01539174 ·Status: WITHDRAWN ·Phase: PHASE2
-
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
NCT00193479 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma
NCT00983944 ·Status: WITHDRAWN ·Phase: PHASE2
-
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies
NCT00072514 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma
NCT00005631 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
NCT00005959 ·Status: UNKNOWN ·Phase: PHASE2
-
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma
NCT00003595 ·Status: COMPLETED ·Phase: PHASE3
-
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT00376961 ·Status: COMPLETED ·Phase: PHASE2
-
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
NCT00295932 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma
NCT00193492 ·Status: COMPLETED ·Phase: PHASE2